<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To validate up-to-date policy of immunosuppressive therapy of patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) which has developed either at <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> phase of <z:hpo ids='HP_0006562'>viral hepatitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: 16 patients with AA detected within 6 months (9 patients) or 12-36 months (7 patients) after <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0006562'>viral hepatitis</z:hpo> received immunosuppressive therapy (antilymphocytic globulin, <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, splenectomy) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Posthepatitis <z:hpo ids='HP_0001915'>aplastic anemias</z:hpo> ran a severe and treatment-resistant course in most cases </plain></SENT>
<SENT sid="3" pm="."><plain>The immunosuppressive therapy produced a response in 44% of the patients </plain></SENT>
<SENT sid="4" pm="."><plain>AA following <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0006562'>viral hepatitis</z:hpo> demands intensive and long-term immunosuppressive therapy with antilymphocytic globulin, <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, splenectomy (in some cases) to achieve a persistent clinicohematological remission </plain></SENT>
</text></document>